Fennec Pharmaceuticals Announces $12.5 Million Debt Financing With Bridge Bank

RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2019 — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS) to be administered by infusion) for the prevention of ototoxicity induced by cisplatin chemotherapy in pediatric patients with solid tumors, announced a $12.5 million […]